Abstract 162P
Background
To evaluate clinical usefulness of hypofractionated radiotherapy (HRT) for pulmonary metastases from hepatocellular carcinoma (HCC) and investigate the prognostic factors affecting treatment outcome.
Methods
From March 2006 to May 2018, 58 patients with less than five pulmonary metastases from HCC who underwent HRT were analyzed retrospectively. Primary endpoint was treatment response rate. Secondary endpoints were progression-free survival, overall survival, prognostic factors affecting treatment outcomes and treatment-related side effects.
Results
The treatment response (complete and partial response) rate was 77.6 %, and the maximum treatment response was presented between 1 to 3 months after completion of HRT. The local control rate was 63.8 %. The median survival time was 16.3 months for all patients. The 1-year and 3-year overall survival rates were 79.3 % and 37.9 %, respectively. The median progression-free survival time was about 5 months and eighty-six percent of the patients (n = 50) showed post-treatment disease progression. Multivariate analysis identified the common prognostic factors for both OS and PFS as the planning target volume and maximal treatment response after HRT. The progression-free survival period was also a prognostic factor for OS in multivariate analysis. The grade 3 and 4 severe toxicities were reported in 4 and 3 patients, respectively.Table:
162P Prognostic factors
OS | PFS | |||||
---|---|---|---|---|---|---|
Median±SD* | p value† | Median±SD* | p value† | |||
Variable | (mo) | UVA | MVA | (mo) | UVA | MVA |
Age | 0.650 | 0.030 | 0.012 | |||
< 60 | 16.2±4.6 | 3.7±3.7 | ||||
≥ 60 | 21.4±7.9 | 4.9±1.3 | ||||
ECOG | 0.097 | 0.401 | ||||
0 | 44.3±17.2 | 8.0±3.0 | ||||
1, 2 | 16.3±4.5 | 3.7±1.3 | ||||
PTV size | 0.017 | 0.003 | 0.027 | 0.003 | ||
< 19 cc | 30.3±8.5 | 5.7±2.0 | ||||
≥ 19 cc | 11.5±2.1 | 3.0±0.3 | ||||
Type I max response | 0.013 | 0.000 | 0.029 | |||
CR+PR | 20.1±4.3 | 5.1±1.6 | ||||
SD+PD | 6.0±1.2 | 1.3±1.1 | ||||
Type II max response | 0.006 | 0.014 | 0.018 | |||
CR+PR+SD | 20.1±3.5 | 5.1±1.3 | ||||
PD | 4.6±1.8 | 1.2±0.1 | ||||
PFS period | 0.001 | 0.003 | ||||
< 5 mon | 10.6±3.5 | |||||
≥ 5 mon | 44.3±11.7 | |||||
Overall | 16.3±4.4 | 4.9±1.2 |
Conclusions
The considerable treatment outcome and acceptable toxicity may indicate clinical usefulness of HRT for patients who have less than five pulmonary metastases from HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract